CAR-T and immunocheckpoint inhibitors showed treatment effect for the patients with refractory and relapsed plasmablasticlymphoma.
2
However, plasmablasticlymphoma is listed in the World Health Organization (WHO) classification as a variant of diffuse large B-cell lymphoma.
3
These results do not support the suggestion in the WHO classification that plasmablasticlymphoma is a variant of diffuse large B-cell lymphoma.
4
Plasmablasticlymphoma has been seen in clinical settings outside those initially reported and has been shown to demonstrate a variety of morphologic patterns.
5
Plasmablasticlymphoma (PBL) is an uncommon, clinically aggressive, Epstein-Barr virus-driven B-cell lymphoma that was initially described in tumors of relatively young human immunodeficiency virus-positive men.